How does communication work in a clinical trial? The roles of the CRA, PM and Sponsor
Efficient communication between the teams involved in a clinical trial is one of the key factors influencing its success. In practice, it is the flow of information between the CRA, the sites and the Sponsor that determines how quickly problems are identified, how effectively decisions are made and how smoothly the project is carried out.
Each of these parties has a different role, and communication between them is based on a clearly defined division of responsibilities. The Clinical Research Associate (CRA) is primarily responsible for ongoing contact with study sites and for overseeing the practical implementation of the trial. The CRA is usually the first to identify potential operational issues, such as recruitment difficulties, protocol deviations or delays in data entry. This information is then passed on to the Project Manager, who acts as the central coordination point for the project.
The PM analyses the reported issues, assesses their impact on the study timeline and quality, and initiates appropriate actions. The PM is also responsible for consolidating information from various areas, such as Monitoring, Data Management, statistics and Pharmacovigilance (PV), and for communicating it to the Sponsor in an organised manner.
The Sponsor plays a strategic and decision-making role. The Sponsor receives regular progress summaries from the PM, along with information on risks and recommendations for further actions. Based on this, decisions are made regarding possible changes to the project, resource allocation or the future direction of the study.
To ensure consistency and transparency in communication, it is standard practice in research projects to develop a Communication Plan. This document defines who communicates with whom, in what form, how often and what scope of information is to be shared. As a result, each project participant has a clear understanding of their communication responsibilities and expectations.
An important element of the Communication Plan is also the escalation pathway. It defines how and at what level issues requiring a rapid response or decision should be reported. For example, operational issues are first analysed by the CRA and PM, while critical problems — such as significant recruitment delays, safety-related matters or risks related to data quality — are escalated to the Sponsor. A clearly defined escalation pathway helps avoid delays in decision-making and minimises the risk of communication chaos.
Communication between the CRA, PM and Sponsor usually takes place in a structured way — through regular project meetings, status reports and ongoing ad hoc communication in situations requiring a quick response. At the same time, it is crucial to adjust the level of detail appropriately: the CRA works with detailed data, the PM aggregates and interprets it, and the Sponsor receives a concise overview of the situation that supports decision-making.
In summary, effective communication in a clinical trial is based not only on the regular flow of information, but also on clearly defined rules and structures, such as the Communication Plan and escalation pathway. These elements ensure transparency, enable a quick response to problems and support the efficient implementation of the project.
